WCN26-7499 Effects of Genetic and Pharmacologic Inhibition of SGLT2 and Dual SGLT1/2 on Salt-Sensitive Hypertension and Renal Injury in Dahl SS Rats

Read full text Summarise with VIRAT
Authors: Olha Kravtsova, Timo Rieg, Ganesh V. Halade, Alexander Staruschenko
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Sodium–glucose cotransporter 2 inhibitors (SGLT2i), initially developed for glycemic control in type 2 diabetes, have since been shown to exert profound cardiovascular and renal protective effects. The recent FDA approval of the dual SGLT1/2 inhibitor sotagliflozin (Sota) for heart failure with preserved ejection fraction (HFpEF) further underscores the broad therapeutic potential of SGLT inhibition. However, the mechanistic roles of SGLT2 and dual SGLT1/2 inhibition in salt-sensitive hypertension (SS HTN) remain poorly understood.

Fields of Study & Subjects

Blood Pressure and Hypertension Studies Diabetes Treatment and Management Chronic Kidney Disease and Diabetes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105045–105045
Publication date
25 March 2026
Language
EN